Of note, severe immune deficiency at switch to second‐line ART was close to 60% in the rest of SSA as compared to 26% in Southern Africa, where 100% of clinic sites had routine CD4 and VL monitoring. The gene discussed is CD4; the disease is Immunodeficiency.